Tobramycin Ophthalmic Solution, USP 0.3% (Sterile)

Manufacturer
Lake Erie Medical DBA Quality Care Products LLC
Effective date
2016-09-21
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
legacy-cache
Hydrated at
2026-08-02 01:22:59

Label at a glance#

ProductTobramycin
Active ingredientTOBRAMYCIN
Label structure12 sections

Indications and uses

Tobramycin Ophthalmic Solution, USP 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of Tobramycin Ophthalmic Solution,USP 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children.

Dosage and administration

In mild to moderate disease, instill one or two drops into the affected eye(s) every four hours. In severe infections, instill two drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation. DO NOT USE IF IMPRINTED NECKBAND IS NOT INTACT. FOR TOPICAL OPHTHALMIC USE ONLY

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

DESCRIPTION

DESCRIPTION SECTION

Tobramycin Ophthalmic Solution, USP 0.3% is a sterile topical ophthalmic antibiotic formulation prepared specifically for topical therapy of external ophthalmic infections.

Each mL contains

Active: Tobramycin 3 mg (0.3%). Inactives: Boric Acid, Sodium Sulfate, Sodium Chloride, Tyloxapol and Purified Water. Sodium Hydroxide and/or Sulfuric Acid (to adjust pH). Tobramycin Ophthalmic Solution, USP 0.3% has a pH range between 7.0 and 8.0 and an osmolality of 260-320 mOsm/kg.

Preservative Added: Benzalkonium Chloride 0.1 mg (0.01%).

Tobramycin is a water-soluble aminoglycoside antibiotic active against a wide variety of gram-negative and gram-positive ophthalmic pathogens.

The chemical structure of tobramycin is

Tobramycin (structural formula)
Tobramycin (structural formula)

Molecular weight: 467.52

Molecular formula: C18H37N5O9

Chemical name:

(2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

In Vitro Data: In vitro studies have demonstrated tobramycin is active against susceptible strains of the following microorganisms: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains.

Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae.

Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. Bacterial susceptibility studies demonstrate that in some cases, microorganisms resistant to gentamicin retain susceptibility to tobramycin.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Tobramycin Ophthalmic Solution, USP 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of Tobramycin Ophthalmic Solution,USP 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Tobramycin Ophthalmic Solution,USP 0.3% is contraindicated in patients with known hypersensitivity to any of its components.

WARNINGS

WARNINGS SECTION

FOR TOPICAL OPHTHALMIC USE ONLY - NOT FOR INJECTION INTO THE EYE

Sensitivity to topically applied aminoglycosides may occur in some patients. If a sensitivity reaction to Tobramycin Ophthalmic Solution, USP 0.3% occurs, discontinue use.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

As with other antibiotic preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated. Cross-sensitivity to other aminoglycoside antibiotics may occur; if hypersensitivity develops with this product, discontinue use and institute appropriate therapy. Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis.

Information For Patients

INFORMATION FOR PATIENTS SECTION

Do not touch dropper tip to any surface, as this may contaminate the solution.

Pregnancy Category B

SPL UNCLASSIFIED SECTION

Reproduction studies in three types of animals at doses up to thirty-three times the normal human systemic dose have revealed no evidence of impaired fertility or harm to the fetus due to tobramycin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

Because of the potential for adverse reactions in nursing infants from Tobramycin Ophthalmic Solution, USP 0.3%, a decision should be made whether to discontinue nursing the infant or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients below the age of two months has not been established.

Geriatric Use

GERIATRIC USE SECTION

No overall clinical differences in safety or effectiveness have been observed between elderly and younger patients.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The most frequent adverse reactions to Tobramycin Ophthalmic Solution are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema. These reactions occur in less than three of 100 patients treated with tobramycin. Similar reactions may occur with the topical use of other aminoglycoside antibiotics. Other adverse reactions have not been reported from tobramycin therapy; however, if topical ocular tobramycin is administered concomitantly with systemic aminoglycoside antibiotics, care should be taken to monitor the total serum concentration.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb, a division of Valeant Pharmaceuticals North America LLC, at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

OVERDOSAGE SECTION

Clinically apparent signs and symptoms of an overdose of Tobramycin Ophthalmic Solution, USP 0.3% (punctate keratitis, erythema, increased lacrimation, edema and lid itching) may be similar to adverse reaction effects seen in some patients.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

In mild to moderate disease, instill one or two drops into the affected eye(s) every four hours. In severe infections, instill two drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.

DO NOT USE IF IMPRINTED NECKBAND IS NOT INTACT.

FOR TOPICAL OPHTHALMIC USE ONLY

HOW SUPPLIED

HOW SUPPLIED SECTION

Tobramycin Ophthalmic Solution USP, 0.3% is supplied in a plastic bottle with a controlled drop tip and a tan polypropylene cap in the following size:

NDC 55700-380-05 mL bottle (5 mL fill)

Storage

Store at 2°-25°C (36°-77°F). Avoid excessive heat.

KEEP OUT OF REACH OF CHILDREN.

Revised July 2016

Bausch + Lomb, a division of Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807 USA

©Bausch & Lomb Incorporated

9116803 (folded)

9116903 (flat)

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

image descriptionimage description

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
Data codeQR Code55700038005\LOT\EXPscan0091.jpg

FDA-Initiated Inactive NDC Indexing#

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
55700-380-05ML - Milliliter55700-3800f85096e-2bb8-468f-995d-9a0d2fc9aa4c12016-10-06
24208-290-05ML - Milliliter24208-2905f762bed-556c-4aa5-9191-6d1fd6c37c5412012-07-24

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 8 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
55700-38055700-380-05
24208-290

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A064052-001TOBRAMYCINTOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-29

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A064052-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-2984e616aacf4f…
2026-08-18 06:07:402026-07A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-29caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-29011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-2931067a03dcf5…
2025-08-23 18:47 UTC2025-08A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-296a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-29fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-29b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-2903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-292680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-295bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-29d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-29d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-2979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-29301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-291e350fbaab3a…
2024-05-31 18:47 UTC2024-05A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-298072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-295c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-295d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-294b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-2974a2ff9319b5…
2022-03-09 01:35 UTC2022-03A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-29bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-29782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-2987673890dc5c…
2021-03-12 10:30 UTC2021-03A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-295aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-298869cabd3fbd…
2020-11-12 02:37 UTC2020-11A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-29c0c555d07b60…
2019-12-14 00:12 UTC2019-12A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-293f01610625f2…
2019-09-15 20:21 UTC2019-09A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-29b00525d2431f…
2019-07-19 19:46 UTC2019-07A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-29ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-296a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-291c564ffb4f44…
2023-12-20 04:57 UTC2023-12A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-29ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-29a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-299b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-29a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-293f0d92c62455…
2023-05-13 08:27 UTC2023-05A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-29053a50430f4f…
2023-01-26 05:58 UTC2023-01A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-293bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-293a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A064052-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT1993-11-29f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A064052-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A064052-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A064052-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A064052-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A064052-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A064052-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A064052-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A064052-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A064052-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A064052-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A064052-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A064052-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A064052-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A064052-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A064052-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A064052-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A064052-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A064052-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A064052-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A064052-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A064052-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A064052-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A064052-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A064052-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A064052-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A064052-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A064052-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A064052-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A064052-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A064052-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A064052-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A064052-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A064052-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A064052-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A064052-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A064052-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A064052-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A064052-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A064052-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A064052-001AT1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
TobramycinTOBRAMYCINBausch & Lomb Incorporateda5693ec9-d2f7-4d45-90b0-a113c54840d72023-11-01Warnings, Adverse reactionsExact identifier
ndc (product): 24208-290
6a9a67ef-adfa-4e2c-9065-575856996f2c5d9c5fda-2f15-4a5a-afa6-18b1bc9c51b32021-04-16Warnings, Adverse reactionsExact identifier
spl set id: 5d9c5fda-2f15-4a5a-afa6-18b1bc9c51b3

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.